News

Please note that Colibri Scientific will be closed for normal operations on Monday 19th September 2022.

During this time, we will operate an emergency Service.

Great week last week at OCT in Barcelona for our Managing Director Sue Keeler and our Business Development Manager Charles Stewart.

Some fantastic connections were made – thank you to those of you who stopped by our stand to talk. To those of you we didn’t get the chance to speak with, please feel free to get in touch with any questions.

We hope to see many of you at OCT London in June!

Welcome to The Hummingbird.

The Hummingbird will keep you informed on our evolving and growing business as well as share current industry hot topics.

Subscribe and follow us on LinkedIn and Twitter so you don’t miss out on anything!

To read the full newsletter please Click the Link Below!

The Humminbird March 2022

Colibri Scientific is looking for a vibrant Project Manager / Project Co-ordinator (dependant on experience) to lead sample operations for early phase clinical trials. The role is primarily office based although the option to work a 1 day per week working from home is available.

Colibri Scientific is a growing company which provides personalised operational and scientific clinical sample services to clinical investigators, biotechnology and pharmaceutical companies running Phase 1 and 2 multi-centre studies.

We have built an excellent reputation for having a flexible approach to meeting our client’s particular needs so the successful candidate must have a preference for non-routine ways of working.

Based in Wilmslow, we are a family friendly company, therefore, can tailor working hours to suit the successful applicant.

For full Job description please see link below:

Project Manager Job Description

• Application deadline: 19/03/2022

• If you have any queries please don’t hesitate to contact me at charles.stewart@colibriscientific.co.uk.

Alderley Park, Cheshire Infex Therapeutics has today announced a deal with Colibri Scientific, to provide logistics and sample operational services for Infex’s RESP-X program.

RESP-X is an anti-virulence therapy in-licensed from Japanese pharma company Shionogi. It is designed to help the body tackle Pseudomonas aeruginosa infections, a hard to treat drug-resistant pathogen recognised by the WHO as a critical threat to human health. A novel humanised monoclonal antibody, RESP-X does not kill bacteria directly but deactivates a mechanism that prevents the immune system from acting against the infection.

Dr Peter Jackson, CEO of Infex Therapeutics, said: “I am delighted to see Infex working with Colibri Scientific to support for our RESP-X program. Colibri Scientific are a key part of the local scientific community, and collaborations such as this really showcase the North West as a UK centre of excellence in infectious disease research.

“RESP-X is designed as a preventative treatment against non-cystic fibrosis bronchiectasis,
a long-term condition where the airways of the lungs become abnormally widened, leading to a build-up of excess mucus that can make the lungs more vulnerable to infection. Patients can become chronically infected with Pseudomonas, significantly reducing their quality of life. There is high, unmet need, with millions of patients worldwide at risk of this condition, and no approved preventative therapy.”

Sue Keeler, Managing Director for Colibri Scientific, said “We are delighted to announce that Infex Therapeutics has taken the decision to partner with Colibri Scientific to provide sample operational, and logistics services for their RESP-X program.”

Welcome to The Hummingbird.

The Hummingbird will keep you informed on our evolving and growing business as well as share current industry hot topics.

Subscribe and follow us on LinkedIn and Twitter so you don’t miss out on anything!

To read the full newsletter please Click the Link Below!

The Hummingbird Newsletter